# Annovis Bio, Inc. (NYSE: ANVS)

> Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). Its lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action.

Buntanetap is an investigational drug candidate that is still being studied in clinical trials.

## Company
- [About Us](https://www.annovisbio.com/about-us): Mission, management team, and board of directors
- [Our Science](https://www.annovisbio.com/our-science): How buntanetap works
- [Pipeline](https://www.annovisbio.com/pipeline): Buntanetap programs in Alzheimer's and Parkinson's diseases, with clinical trial results
- [Intellectual Property](https://www.annovisbio.com/intellectual-property): Patents covering buntanetap

## Clinical trials
- [Pivotal Phase 3 Alzheimer's Study](https://www.annovisbio.com/alzheimers-disease): Double-blind study of buntanetap in early Alzheimer's disease (NCT06709014), fully enrolled with 862 patients
- [Alzheimer's Open-Label Extension](https://www.annovisbio.com/alzheimers-open-label-extenstion): Continued buntanetap access for Phase 3 participants
- [Parkinson's Open-Label Study](https://www.annovisbio.com/parkinsons-disease): Long-term study of buntanetap in Parkinson's disease (NCT07284784)
- [Patient Portal](https://www.annovisbio.com/patient-portal): Trial eligibility and how to participate
- [Expanded Access Policy](https://www.annovisbio.com/expanded-access-policy)

## News and investors
- [Press Releases](https://www.annovisbio.com/press-release): All company announcements
- [Investor Relations](https://www.annovisbio.com/investors-relations): Investor overview, presentations, and events
- [SEC Filings](https://www.annovisbio.com/sec-fillings)
- [Quarterly Earnings](https://www.annovisbio.com/quarterly-earnings)
- [Investor FAQ](https://www.annovisbio.com/faq)
- [Publications](https://www.annovisbio.com/publications): Peer-reviewed research on buntanetap
- [Posters & Presentations](https://www.annovisbio.com/posters-presentations): Scientific conference materials

## Contact
- Investor relations: ir@annovisbio.com
- Clinical trials: clinicaltrials@annovisbio.com
- General: info@annovisbio.com, +1 (484) 875-3192, 101 Lindenwood Drive, Suite 225, Malvern, PA 19355